Canada’s medical devices deals in Q1 2021: Deals Analysis
Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here
X

Canada’s medical devices industry sees a rise of 125% in deal activity in Q1 2021

06 May 2021 (Last Updated May 6th, 2021 18:35)

Led by $115m private equity deal with Kardium, Canada’s medical devices industry saw a rise of 125% in overall deal activity during Q1 2021, when compared with the last four-quarter average, according to GlobalData’s deals database.

  • Embed this chart

    Embed this chart into your website

    Copy and paste the image source into your website to display the chart.

A total of 27 deals worth $489.76m were announced in Q1 2021, compared with the last four-quarter average of 12 deals.

venture financing was the leading category in the quarter with 11 deals which accounted for 40.7% of all deals.

In second place was M&A with ten deals, followed by private equity with six transactions, respectively accounting for 37.04% and 22.2% of overall deal activity in the Canada’s medical devices industry during the quarter.

In terms of value of deals, private equity was the leading deal category in Canada’s medical devices industry with total deals worth $203.96m, while M&A and venture financing deals totalled $182.98m and $102.82m respectively.

Canada medical devices industry deals in Q1 2021: Top deals

The top five medical devices industry deals accounted for 84.6% of the overall value during Q1 2021.

The combined value of the top five medical devices deals stood at $414.21m, against the overall value of $489.76m recorded for the quarter.

The top five medical devices industry deals of Q1 2021 tracked by GlobalData were:

1) Fidelity Management & Research and T Rowe Price Associates’ $115m private equity deal with Kardium

2) The $110m acquisition of 7D Surgical by SeaSpine

3) TELUS Health Solutions’ $70m asset transaction with Babylon Healthcare Services

4) The $65m venture financing deal with CorVista Health by Ambix Life Science Fund I and MedVenture Partners

5) Caisse de dépôt et placement du Québec’s private equity with Savaria for $54.21m.